A Phase III, Open-Label, Randomized Study Of Atezolizumab (Mpdl3280a, Anti-Pd-L1 Antibody) In Combination With Carboplatin Paclitaxel With Or Without
Posted Date: May 15, 2019
- Investigator: John Morris
- Type of Study: Drug
The purpose of this study is to look at the effects, good or bad, of atezolizumab on you and the specific type of lung cancer (non-small cell lung cancer [NSCLC]) you are have. Atezolizumab is an experimental drug, which means that health authorities have not approved atezolizumab for the treatment
Criteria:
To Be Eligible To Participate, Patients Must Have Been Diagnosed With Stage Iv Non-Squamous Non-Smal
Keywords:
Cancer, Go29436, Lung, Non Small Cell, Non Squamous
For More Information:
Uc Cancer Center
513-584-7698
kastla@uc.edu